Shandong Sinder Technology: HKEX filing lapses after 6 months, previously filed for H-share listing with ICBC International and CLSA as joint sponsors

NewTimeSpace News: On 17 August 2026, the listing application of Shandong Sinder Technology Co., Ltd. filed with the Hong Kong Stock Exchange on 16 February 2026 has lapsed as it exceeded the six-month validity period, with ICBC International and Zhongtai International having acted as joint sponsors at the time of filing. Established in 1999, the Company is a leading animal health enterprise in China, engaged in the R&D, production and sales of a full range of animal health and supporting products, covering veterinary biologics (vaccines, antibodies, transfer factors, etc.), Chinese veterinary medicines, chemical pharmaceutical preparations, animal feed and feed additives, for the prevention, diagnosis, treatment and control of diseases in poultry, livestock, aquatic animals and pets.

According to CIC, by 2024 revenue, the Company ranked ninth in China's animal health market (among domestic brands) and in the top three in China's poultry veterinary biologics market. As of 30 September 2025, the Company operated 4 production bases and 34 GMP-certified production lines, holding 43 valid and effective new veterinary drug registration certificates (including national Class I and II) and 82 invention patents, and had established a precision prevention and control service model covering precision epidemiology, precision customization and precision evaluation.

Financially, revenue for the first nine months of 2025 increased by 25.2% compared with the same period of 2024, while profit before tax increased by more than 100%; R&D investment accounted for 7.5% of revenue in the first nine months of 2025. To proceed with a Hong Kong listing, the Company would need to refile its application.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.